Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 421

1.

Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials.

Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW.

Am J Cardiol. 2016 Jul 1;118(1):6-16. doi: 10.1016/j.amjcard.2016.04.005. Epub 2016 Apr 20.

PMID:
27181566
2.

What the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis.

Lansky AJ, Ng VG.

Circ Cardiovasc Interv. 2016 May;9(5). pii: e003861. doi: 10.1161/CIRCINTERVENTIONS.116.003861. No abstract available.

PMID:
27162219
3.

Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry.

Iñiguez A, Brener SJ, Jiménez VA, Maehara A, Mintz GS, Xu K, Weisz G, Lansky AJ, De Bruyne B, Serruys PW, Stone GW.

EuroIntervention. 2016 Apr 20;11(13):1468-74. doi: 10.4244/EIJV11I13A285.

4.

Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial.

Ng VG, Mori K, Costa RA, Kish M, Mehran R, Urata H, Saku K, Stone GW, Lansky AJ.

Int J Cardiol. 2016 Mar 15;207:269-76. doi: 10.1016/j.ijcard.2016.01.013. Epub 2016 Jan 6.

PMID:
26808991
5.

Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).

Lansky AJ, Kastrati A, Edelman ER, Parise H, Ng VG, Ormiston J, Wijns W, Byrne RA.

Am J Cardiol. 2016 Feb 15;117(4):532-8. doi: 10.1016/j.amjcard.2015.11.044. Epub 2015 Dec 7.

PMID:
26762729
6.

Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, Lansky AJ, Witzenbichler B, Kornowski R, Guagliumi G, Dudek D, Stone GW.

JACC Cardiovasc Interv. 2015 Dec 28;8(15):1966-74. doi: 10.1016/j.jcin.2015.08.031.

PMID:
26738667
7.

Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials.

Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW.

Eur Heart J Acute Cardiovasc Care. 2015 Dec 31. pii: 2048872615624848. [Epub ahead of print]

PMID:
26722003
8.

Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials).

Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ.

Am J Cardiol. 2016 Jan 15;117(2):186-91. doi: 10.1016/j.amjcard.2015.10.029. Epub 2015 Dec 1.

PMID:
26704028
9.

Coronary Microvascular Dysfunction: Does Sex Matter?

Lansky AJ, Pietras C.

JACC Cardiovasc Interv. 2015 Sep;8(11):1442-4. doi: 10.1016/j.jcin.2015.04.026. No abstract available.

PMID:
26404196
10.

Lumen Measurements From Quantitative Coronary Angiography and IVUS: A PROSPECT Substudy.

Goto K, Mintz GS, Litherland C, Lansky AJ, Weisz G, McPherson JA, De Bruyne B, Serruys PW, Stone GW, Maehara A.

JACC Cardiovasc Imaging. 2015 Sep 2. pii: S1936-878X(15)00542-2. doi: 10.1016/j.jcmg.2015.07.006. [Epub ahead of print] No abstract available.

PMID:
26363838
11.

The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Classification System: A Taxonomy for Young Women With Acute Myocardial Infarction.

Spatz ES, Curry LA, Masoudi FA, Zhou S, Strait KM, Gross CP, Curtis JP, Lansky AJ, Soares Barreto-Filho JA, Lampropulos JF, Bueno H, Chaudhry SI, D'Onofrio G, Safdar B, Dreyer RP, Murugiah K, Spertus JA, Krumholz HM.

Circulation. 2015 Nov 3;132(18):1710-8. doi: 10.1161/CIRCULATIONAHA.115.016502. Epub 2015 Sep 8.

PMID:
26350057
12.

Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction.

Behan MW, Haude M, Oldroyd KG, Lansky AJ, James S, Baumbach A.

EuroIntervention. 2015 Jul;11(3):361-3. doi: 10.4244/EIJV11I3A70. No abstract available.

13.

Tools and Techniques - Clinical: Embolic protection devices in transcatheter aortic valve implantation.

Van Gils L, Baumbach A, Himbert D, Lansky AJ, Vahanian A, Van Mieghem NM.

EuroIntervention. 2015 Jun;11(2):247-8. doi: 10.4244/EIJV11I2A45. No abstract available.

14.

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.

Lansky AJ, Schofer J, Tchetche D, Stella P, Pietras CG, Parise H, Abrams K, Forrest JK, Cleman M, Reinöhl J, Cuisset T, Blackman D, Bolotin G, Spitzer S, Kappert U, Gilard M, Modine T, Hildick-Smith D, Haude M, Margolis P, Brickman AM, Voros S, Baumbach A.

Eur Heart J. 2015 Aug 14;36(31):2070-2078. Epub 2015 May 19.

PMID:
25990342
15.

Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial.

Souza CF, Doi H, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Xu K, Mehran R, Stone GW, Maehara A.

Coron Artery Dis. 2015 Sep;26(6):469-75. doi: 10.1097/MCA.0000000000000251.

PMID:
25919902
16.

Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.

Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ.

EuroIntervention. 2015 May;11(1):75-84. doi: 10.4244/EIJY15M04_01.

17.

Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials.

Gao Z, Zhang R, Xu B, Yang Y, Ma C, Li H, Chen S, Han Y, Yuan Z, Lansky AJ, Guan C, Leon MB, Gao R; TARGET Investigators.

Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:734-43. doi: 10.1002/ccd.25861. Epub 2015 Feb 19.

PMID:
25678281
18.

Prognostic utility of myocardial blush grade after PCI in patients with NSTE-ACS: Analysis from the ACUITY trial.

Ng VG, Lansky AJ, Toro S, Parise H, Cristea E, Mehran R, Stone GW.

Catheter Cardiovasc Interv. 2015 Jan 30. doi: 10.1002/ccd.25865. [Epub ahead of print]

PMID:
25641255
19.

Local delivery of paclitaxel in the treatment of peripheral arterial disease.

Ng VG, Mena C, Pietras C, Lansky AJ.

Eur J Clin Invest. 2015 Mar;45(3):333-45. doi: 10.1111/eci.12407. Epub 2015 Feb 14. Review.

PMID:
25615282
20.

Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).

Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW.

Am J Cardiol. 2014 Dec 1;114(11):1638-45. doi: 10.1016/j.amjcard.2014.09.003. Epub 2014 Sep 18.

PMID:
25312637
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk